XOMA (XOMAO.PFD) Debt-to-Equity : 1.40 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is XOMA Debt-to-Equity?

XOMA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.60 Mil. XOMA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $118.85 Mil. XOMA's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $88.72 Mil. XOMA's debt to equity for the quarter that ended in Dec. 2023 was 1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for XOMA's Debt-to-Equity or its related term are showing as below:

XOMAO.PFD' s Debt-to-Equity Range Over the Past 10 Years
Min: -21.08 Med: 0.75 Max: 11.39
Current: 1.4

During the past 13 years, the highest Debt-to-Equity Ratio of XOMA was 11.39. The lowest was -21.08. And the median was 0.75.

XOMAO.PFD's Debt-to-Equity is ranked worse than
91.67% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs XOMAO.PFD: 1.40

XOMA Debt-to-Equity Historical Data

The historical data trend for XOMA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Debt-to-Equity Chart

XOMA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.75

0.25

1.40

XOMA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	1.40

Competitive Comparison of XOMA's Debt-to-Equity

For the Biotechnology subindustry, XOMA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where XOMA's Debt-to-Equity falls into.

XOMA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

XOMA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.597	+	118.853)	/	88.721
	=	1.40

XOMA's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.597	+	118.853)	/	88.721
	=	1.40

XOMA (NAS:XOMAO.PFD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

XOMA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of XOMA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA (XOMAO.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMAO.PFD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

XOMAP.PFD:USA XOMA:USA X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Executives

Bradley Sitko	officer: Chief Investment Officer	C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes	director, officer: Interim CEO	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Heather L Franklin	director	C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Barbara Kosacz	director	3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta	officer: Chief Business Officer	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Matthew D Perry	director, other: See Explanation of Responses	ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104